STOCKHOLM, April 21, 2021 /PRNewswire/ -- IRRAS, a
commercial-stage medical technology company with a comprehensive
portfolio of innovative products for neurocritical care, today
announced that its Board of Directors has appointed Will Martin as President and Chief Executive
Officer (CEO) of the Company. Will
Martin, currently the company's President and Chief
Commercial Officer, will assume his new role on July 1, 2021, He will succeed current CEO,
Kleanthis G. Xanthopoulos, Ph.D.,
who will remain on IRRAS' Board of Directors and will serve as a
company advisor during a transition period.
Will Martin joined IRRAS in
2018. Prior to IRRAS, he served as General Manager of the
Peripheral Vascular devices business for Philips Healthcare, Vice
President of Commercial Operations at AtheroMed, Inc. prior to its
acquisition by Volcano Corporation, and held other key commercial
roles at other life science companies. He received a BA degree from
The University of Notre Dame and an MBA
from Johns Hopkins University and also
served as a Lieutenant in the United
States Navy.
"Dr. Xanthopoulos has built a strong medical and technical
foundation for IRRAS within the expanding market for neurocritical
care. Critical fundamental elements, such as establishing in-house
manufacturing, strengthening our organization, securing key
regulatory approvals, and growing sales, are now in place," said
Marios Fotiadis, Chairman of IRRAS'
Board of Directors. "We have been planning for a potential
transition since Will Martin was
promoted to President in June. With IRRAS now positioned for faster
commercial expansion, the timing is right."
"During my time at IRRAS, we've made meaningful progress in
building a strong foundation for future expansion across all areas
of our business," said Will Martin.
"I am incredibly excited to lead our Company through its next phase
of growth and will work closely with our team members to become a
global leader in neurocritical care."
"We have now treated over 200 patients with IRRAflow at
more than 30 leading institutions in 18 countries across 3
continents with extremely positive treatment outcomes. Our other
product line, Hummingbird, is well positioned to increase market
share globally in the established market for intracranial pressure
monitoring," said Dr. Xanthopoulos. "During Q1, we more than
doubled the number of commercial capital systems in the US, and
sales are growing faster than ever before. The stage is set, and
the time is right for Will to take over as IRRAS' President and
CEO. With his strong commercial skills and my continued engagement,
IRRAS will have the right set up for the next step of growth and
financial value creation."
About IRRAS
IRRAS is a global medical care company focused on innovative
medical solutions to improve the lives of critically ill patients.
IRRAS designs, develops, and commercializes neurocritical care
products that transform patient outcomes and decrease the overall
cost of care by addressing complications associated with current
treatment methodologies. IRRAS markets and sells its comprehensive,
innovative IRRAflow and Hummingbird ICP Monitoring
product lines to hospitals worldwide through its direct sales
organization in the United States
and select European countries as well as an international network
of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in
Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker: IRRAS).
For more information, please contact:
USA
Kleanthis G. Xanthopoulos, Ph.D.
CEO
ir@irras.com
Europe
Sabina Berlin
CFO
+46 73 951 95 02
sabina.berlin@irras.com
This information is information that IRRAS is obliged to
disclose pursuant to the EU Market Abuse Regulation. The
information was released for public disclosure, through the agency
of the contact person above, on April 21,
2021 at 20:00 (CET).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/irras/r/irras-promotes-will-martin-to-chief-executive-officer,c3330585
The following files are available for download:
https://mb.cision.com/Main/16550/3330585/1405222.pdf
|
IRRAS Promotes Will
Martin to Chief Executive Officer
|